ArticleFrontiers in oncology2026
Cardiometabolic comorbidities and prostate cancer risk: evidence from the prostate, lung, colorectal, and ovarian cancer screening trial.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to explore the association between cardiometabolic diseases (CMDs) involving diabetes and the risk of prostate cancer (PCa) as well as its mortality. Methods: The population-based cohort, comprising 71, 566 participants, was derived from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. CMDs encompassed three conditions, namely diabetes, heart diseases, and stroke. Multivariable Cox proportional hazards and competing risk regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for assessing associations between individual diabetes, coexisting CMDs, and PCa incidence and mortality. Results: At baseline, 12, 979 participants had at least one CMD, while 2, 391 had two or more concurrent CMDs. Over a 17-year mean follow-up, 8, 263 participants were diagnosed with PCa. Participants with baseline diabetes exhibited an 18% elevated risk of developing PCa compared with CMD-free counterparts (HR: 1.18, 95% CI: 1.08~1.29). Among participants with multimorbidity, only diabetes-heart disease comorbidity was significantly associated with an elevated risk of PCa incidence (HR: 1.31, 95% CI: 1.09~1.59). Neither diabetes, heart disease, nor stroke had a statistically significant association with PCa-specific mortality risk. However, compared with CMD-free individuals, those with a single type of CMD exhibited a significantly reduced risk of non-aggressive PCa-specific mortality (HR: 0.50, 95% CI: 0.26~0.99). Conclusions: Baseline diabetes was independently associated with an increased incidence of PCa, and the comorbidity of diabetes with heart disease further amplified this risk. The presence of a single CMD reduced the risk of non-invasive PCa-specific mortality in affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.